Abstracts tagged "Biologic agents"

Abstract Number: 1040 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Long Term Rituximab Use in Rheumatoid Arthritis – Results from the British Society of Rheumatology Biologics Register
Alexander G.S. Oldroyd¹, Deborah P.M. Symmons¹, Lianne Kearsley-Fleet¹, Kath Watson¹, Mark Lunt², Jamie Sergeant¹, Kimme L. Hyrich¹ and on behalf of the BSRBR-RA, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Analysis of long term continuation of biologics in rheumatoid arthritis (RA) is considered a valid surrogate for treatment effectiveness and safety. Only a small…
Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Brandon Arnieri¹, Khaled Sarsour¹, David Oliveri¹, Attila Pethö-Schramm², Avani Shah¹ and George Quartey¹, ¹Genentech, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…
Abstract Number: 2759 • 2015 ACR/ARHP Annual Meeting
Long-Term Survival of Biological Therapy in Rheumatoid Arthritis Elderly Patients in Clinical Practice
Cristina Lajas¹, Alejandro Gomez-Gomez¹, Luis Rodriguez-Rodriguez², Leticia Leon², Cristina Vadillo¹, Dalifer Freites Núñez¹, Pilar Macarrón¹, José María Leal Pozuelo², Juan A Jover¹ and Lydia Abasolo², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: With the increasingly widespread use of biological agents (BA), a thorough knowledge of their long-term behavior in clinical practice is fundamental. The purpose of…
Abstract Number: 445 • 2015 ACR/ARHP Annual Meeting
Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from a Rheumatoid Arthritis Cohort
Arthur Lau¹, Mohammad Movahedi^2,3, Mark Tatangelo⁴, Claire Bombardier^3,5,6 and OBRI investigators, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Clinical Decision Making and Health Care, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Clinical evidence suggests concomitant treatment with a biologic Disease-Modifying Antirheumatic Drug (bDMARD) and a conventional synthetic DMARD (csDMARD), especially with methotrexate (MTX) has greater…
Abstract Number: 1046 • 2015 ACR/ARHP Annual Meeting
Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese¹, Joel M. Kremer², Cynthia Kartman³, Douglas E. Schlichting³, Li Xie³, Tara Carmack⁴, William L. Macias³ and Josef S. Smolen⁵, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Durham, NC, ⁵Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib, an oral inhibitor of JAK1/JAK2, improved disease activity with an acceptable safety profile in a phase 3 study (RA-BEACON) of patients with active…
Abstract Number: 1654 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate-Naïve Patients with Rheumatoid Arthritis
Roy Fleischmann¹, Janet E. Pope², Vanita Tongbram³, Derek Tang⁴, James Chung⁵, David Collier⁵, Shilpa Urs³, Kerigo Ndirangu³, George A. Wells⁶ and Ronald F. van Vollenhoven⁷, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Western Ontario, London, ON, Canada, ³ICON Plc., Morristown, NJ, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada, ⁷Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Several published randomized head-to-head trials in rheumatoid arthritis (RA) have compared TNFi-MTX with triple therapy (MTX + hydroxychloroquine + sulfasalazine) in MTX-naive patients (MTX-Ns)…
Abstract Number: 2764 • 2015 ACR/ARHP Annual Meeting
Head-to-Head Comparison of the Retention Rate of First Biologics in Elderly Patients with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Masatoshi Hayashi¹, Toshihisa Kanamono², Hiroyuki Matsubara³, Toshihisa Kojima⁴, Koji Funahashi⁵, Nobunori Takahashi⁴ and Naoki Ishiguro⁶, ¹Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Reumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁵Nagoya University, Nagoya, Japan, ⁶Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: The objective of this report was to clarify and compare the retention rate of first biologics used to treat elderly Japanese patients with rheumatoid…
Abstract Number: 477 • 2015 ACR/ARHP Annual Meeting
On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients
Kentaro Inui¹, Tatsuya Koike², Masahiro Tada³, Yuko Sugioka², Kenji Mamoto⁴, Tadashi Okano⁴, Akira Sakawa⁵, Kenzo Fukushima⁶ and Hiroaki Nakamura⁴, ¹Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic Surgery, Osaka City General Hospital, OSAKA, Japan, ⁴Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka City Juso Hospital, Osaka, Japan, ⁶Orthopaedic Surgery, Fujiidera Municipal Hospital, Fujiidera, Japan
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) are essential in the treatment of rheumatoid arthritis (RA). Biological DMARDs are particularly recommended for patients with active RA…
Abstract Number: 1107 • 2015 ACR/ARHP Annual Meeting
Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark^1,2, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and production of autoantibodies. Treatment of patients with moderate-to-severe SLE with epratuzumab, a humanized…
Abstract Number: 1658 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Affects the Efficacy of First Biological Treatment in RA
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Rheumatoid factor (RF) is considered an important factor in diagnosing rheumatoid arthritis (RA). The association between the treatment efficacy of biological agents and RF…
Abstract Number: 2765 • 2015 ACR/ARHP Annual Meeting
Long-Term Retention Rate of First Biologics in Patients of Age over 75 Years with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Masatoshi Hayashi¹, Toshihisa Kanamono², Hiroyuki Matsubara³, Toshihisa Kojima⁴, Koji Funahashi⁵, Nobunori Takahashi⁴ and Naoki Ishiguro⁶, ¹Department of Orhtopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Reumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁵Nagoya University, Nagoya, Japan, ⁶Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: The objective of this report was to clarify and compare the retention rate of first biologics used to treat elderly Japanese patients with rheumatoid…
Abstract Number: 505 • 2015 ACR/ARHP Annual Meeting
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
Yusuf Yazici¹, Hannah Bernstein¹ and Christopher Swearingen², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pediatrics & Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose: With the availability of multiple biologic agents, each with different modes of action, use of real world registries provide the manner in which to…
Abstract Number: 1108 • 2015 ACR/ARHP Annual Meeting
Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor
Simon Lumb¹, Sarah J. Fleischer², Capucine Daridon², Alison Maloney¹, Anthony Shock¹ and Thomas Dorner², ¹UCB Pharma, Slough, United Kingdom, ²Charité University Medicine Berlin, CC12, Dept. Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Center Berlin (DRFZ), a Leibniz Institute, Berlin, Germany
Background/Purpose: Epratuzumab, a humanized monoclonal antibody targeting CD22, is currently in phase 3 clinical trials in patients with systemic lupus erythematosus (SLE). Previous work suggests…
Abstract Number: 1670 • 2015 ACR/ARHP Annual Meeting
Rapidity of Therapeutic Response of Biologics Compared to Methotrexate Monotherapy in Early RA: A Network Meta-Analysis
Raveendhara R. Bannuru, Mikala Osani, Anbuselvan Dharmarajan, Elizaveta Vaysbrot and Timothy E. McAlindon, Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Rapidity of onset of therapeutic efficacy may be critically important in the management of early RA and may reduce long-term impact of the disease.…
Abstract Number: 2777 • 2015 ACR/ARHP Annual Meeting
Drug Retention Rates of Biologic Monotherapies for Patients with Rheumatoid Arthritis Receiving TNF Inhibiting Fusion Protein Agent and Antibody Agent; From Multicenter Registry in Japan
Hiroyuki Matsubara¹, Masatoshi Hayashi², Nobunori Takahashi³, Toshihisa Kojima³, Koji Funahashi³ and Naoki Ishiguro⁴, ¹Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Department of Orhtopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: In general, drug retention rate reflects the effectiveness and tolerability of the drug. TNF inhibitors include fusion protein agent such as etanercept (ETN) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.